Johnson & Johnson
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joaquin Duato
- Full Time Employees
- 141,700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States of America 08933
- IPO Date
- Jan 2, 1962
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
Company News
Dave Ramsey Says You Need More Than 6% Just to Break Even. Dividend Growth Is One Way to Get There.
CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
J&J's Caplyta meets main goal of bipolar mania study
3 Dividend Stocks Built for Retirement to Buy in September
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20
The Dividend Kings Ranked By Quality Scores (September 2026)
A $100,000 Retirement Dividend Snowball In A Rising-Rate World
Nykredit A S Takes $235.82 Million Position in Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript